News
The Association of Multisite Research Corporations (AMRC) today announced the addition of three new members,Rovia Clinical Research, K2 Medical Research, and Eximia, further expanding its representation of leading multisite research organizations across the United States and internationally.
When Headlands Research was acquired by THL Partners earlier this year, the deal sent a clear signal: consolidation in the clinical trials sector is accelerating. Investors are taking a hard look at the potential of site networks and multisite clinical research corporations (MCRCs) to deliver the scale, quality, and efficiency demanded by sponsors, CROs, and patients.
There’s an ancient Chinese expression that says, “may you live in interesting times.” For the clinical trial industry, the word “interesting” doesn’t even begin to cover the roller-coaster ride of regulatory changes, disappearing grants, and general uncertainty it’s endured over the past six to twelve months.
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
AMRC founding member Headlands Research has announced its pending acquisition by THL Partners, marking an important moment for both the organization and the broader clinical trials sector. The deal reflects the rapidly rising interest of the investment community in the future of multisite clinical research corporations (MCRCs).
WEBINAR - AUGUST 20, 2025
In this informative session, clinical trial professionals will have an opportunity to hear directly from the FDA’s David Burrow on ways industry can advance clinical trial innovation. David will discuss the Center for Drug Evaluation and Research (CDER) Center for Clinical Trial Innovation (C3TI), along with perspectives on the growing role of artificial intelligence and other technologies in trial operations. He will also share valuable opportunities for industry to give FDA important input via C3TI demonstration projects and other initiatives which help shape the global clinical research ecosystem.
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
Access Granted is the Association of Multisite Research Corporations’s (AMRC) initiative for increasing site participation at industry events. This month, we are giving away five free tickets to the inaugural Partnerships with Sites Summit, 15 September 2025, Philadelphia by entering our free prize giveaway.
Derailed a bit at first to discover she’d in fact been hired as a clinical researcher, Byrne realized quickly. “I had found my life’s work.” Or, perhaps more accurately, it found her. And over three decades on, she’s CEO of Javara, a founding member of the Association for Multisite Research Corporations (AMRC) and a leading voice in clinical trial innovation.
The Association of Multisite Research Corporations (AMRC), the leading trade association representing multisite clinical research corporations (MCRCs), announces Jennifer Byrne, CEO of Javara, as its newest member of the Board of Directors.
The Association of Multisite Research Corporations (AMRC), the leading trade association representing multisite clinical research corporations (MCRCs), announces Jennifer Byrne, CEO of Javara, as its newest member of the Board of Directors.
WEBINAR - JUNE 12, 2025
In this candid conversation, representatives from the clinical trial ecosystem will discuss how they can work with sites more effectively. We will use the session to identify key issues and blockers that prevent Sponsors and CROs from engaging with multisite clinical research corporations (MCRCs). We’ll also examine how MCRCs can uniquely address and mitigate some of these obstacles.
The Association of Multisite Research Corporations (AMRC), the leading trade association representing multisite clinical research corporations (MCRCs), announces Jennifer Byrne, CEO of Javara, as its newest member of the Board of Directors.
The prospect of finding new cures for patients is what drives Mona Alqam and her team at Pratia, a Research Site Network with 90+ sites across eight countries. With 1500+ Clinical Trials carried out since 2012 across approximately 85% of all Therapeutic Areas and protocol designs, Pratia has engaged in a wide spectrum of clinical trial activities.
The word ‘bipartisan’ might have been sparsely used since January, but the issue of drug pricing has permeated both sides of the aisle over the last three years. The Biden Administration’s Inflation Reduction Act of 2022 marked a policy shift that empowered Medicare to re-negotiate pricing on some high-cost drugs for the first time. The Trump administration also signalled its stance on the issue last week, introducing a ‘Most Favored Nation’ (MFN) pricing model by way of executive order.
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
The Association of Multisite Research Corporations (AMRC) today announces Pratia, one of the largest and most respected site networks, has joined as the association’s fifteenth member. With this addition, AMRC now represents a collective footprint of nearly 500 research sites, almost 8,000 employees, and approximately 1,500 principal investigators across its member companies, globally.
Hosted by AMRC, this timely webinar offered insights into the evolving federal policy and funding landscape affecting multisite clinical research corporations (MCRCs), with a strong focus on strategic advocacy and the challenges ahead.
WEBINAR - MARCH 26, 2025
The federal policy landscape is shifting—how will it impact multisite clinical research corporations (MCRCs)?
Join Patrick Cooney, a seasoned expert with bipartisan insight into healthcare policy, as we explore the federal government’s priorities and funding outlook for clinical research.
WEBINAR - JANUARY 23, 2025
Operational inefficiency in clinical research: what is it costing Sponsors and CROs?
The Association of Multisite Research Corporations (AMRC) welcomes a panel of experts to discuss the financial and operational impact of inefficiency in clinical trials. We’ll be joined by representatives from regulatory, academic, pharma, and trial sites, who will share their perspectives on the challenges facing the industry and possible solutions to streamline trials, improve data quality, and bring therapies to patients faster.
In a recent interview with E.B. McLindon, CEO of Helios Clinical Research and Director at the Association for Multi-Site Research Corporations (AMRC), McLindon shared his perspective on the mindset needed in the research industry
As part of AMRC's role to advocate for multisite clinical research corporations (MCRC), we responded to the FDA's consultation: Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices; Guidance for Industry - Draft Guidance.
The clinical trial ecosystem has become increasingly complex, with the number of drugs in development nearly doubling between 2012 and 2022. This growth, coupled with rising patient recruitment demands and the need for diverse trial endpoints, has highlighted the limitations of the traditional site model.
The traditional clinical trial model, which relies on independent sites and Principal Investigators (PIs), faces significant inefficiencies, including fragmented processes, delayed start-ups, administrative burdens, and high burnout rates. These inefficiencies contribute to trial delays, missed enrollment targets, and increased costs—estimated at $540,000 per day due to lost prescription sales and trial expenses.
The Association of Multisite Research Corporations (AMRC) has officially launched, marking a transformative step forward in clinical research. This new trade association aims to advance the adoption of multisite clinical research corporations (MCRCs) to enhance efficiency, improve patient safety, and uphold data integrity in clinical trials.
